These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1602806)

  • 1. Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings.
    Foa R; Meloni G; Guarini A; Vignetti M; Marchis D; Tosti S; Tos AG; Vischia F; Mandelli F; Gavosto F
    Leukemia; 1992; 6 Suppl 3():115S-116S. PubMed ID: 1602806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
    Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F
    Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.
    Klingemann HG; Eaves CJ; Barnett MJ; Eaves AC; Hogge DE; Nantel SH; Reece E; Shepherd JD; Sutherland HJ; Phillips GL
    Bone Marrow Transplant; 1994 Sep; 14(3):389-96. PubMed ID: 7994260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine activated killer (LAK) activity in lymphoproliferative disorders.
    Foa R; Fierro MT; Raspadori D; Bonferroni M; Cardona S; Liao XS; Cesano A; Matera L; Gillio Tos A; Tola E
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():153-5. PubMed ID: 2653494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.
    Foa R; Meloni G; Tosti S; Novarino A; Fenu S; Guarini A; Cardona S; Gillio Tos A; Gavosto F; Mandelli F
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():98-102. PubMed ID: 2202476
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
    Fierro MT; Liao XS; Lusso P; Bonferroni M; Matera L; Cesano A; Lista P; Arione R; Forni G; Foa R
    Leukemia; 1988 Jan; 2(1):50-4. PubMed ID: 3257539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation.
    Pati AR; Godder K; Lamb L; Gee A; Henslee-Downey PJ
    Bone Marrow Transplant; 1995 Jun; 15(6):979-81. PubMed ID: 7581101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of postinduction immunotherapy in acute myeloid leukemia.
    Klingemann HG
    Leukemia; 1996 Apr; 10 Suppl 1():S21-2. PubMed ID: 8618464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Has IL2 a role in the management of minimal residual disease for acute leukemia?
    Foa R; Meloni G; Guarini A; Mandelli F; Gavosto F
    Leukemia; 1992 Nov; 6 Suppl 4():92-4. PubMed ID: 1434844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adoptive immunotherapy with interleukin 2 in oncology].
    Favrot M; Bouffet E; Négrier S; Combaret V; Philip I; Philip T
    Bull Cancer; 1990; 77(9):925-31. PubMed ID: 2224165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.
    Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F
    Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
    Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
    Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy with interleukin-2 and allogenic LAK cells in a patient with acute myeloblastic leukemia].
    Parrado A; Casares S; Carmona M; Campo T; Rodríguez Fernández JM
    Sangre (Barc); 1994 Oct; 39(5):393-6. PubMed ID: 7754446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction and postremission strategies in acute myeloid leukemia: what is new?
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2011 Mar; 18(2):83-8. PubMed ID: 21245759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
    Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.